Nationally representative survey data reveals that glucagon-like peptide 1 receptor agonists (GLP-1 RAs) use for obesity treatment more than tripled among US adults without diabetes between 2018 and ...

New UK research reveals that obesity significantly worsens pain, mobility, and daily functioning in older adults with knee ...

Adults who developed severe obesity before the age of 18 are nearly three times more likely than those who developed the ...

Weight-loss surgeries for adolescents increased 15% in the U.S. between 2021 and 2023, even as the Food and Drug ...

The World Health Organization plans to officially back the use of weight-loss drugs to treat obesity in adults for the first ...

Currently, more than 42% of adults in the United States have obesity. Among young people, about 1 in 5 adolescents are also ...

In an internal memo, the World Health Organization signaled its support for anti-obesity drugs like Wegovy and Zepbound, ...

Higher BMI cutoffs are needed to diagnose overweight and obesity in male athletes, researchers reported in a study published ...

The WHO announced its plan to support GLP-1 weight-loss drugs, like Wegovy and Zepbound, to address the global obesity ...

A decision is expected in the fourth quarter of 2025.

Adults with overweight or obesity plus prediabetes maintain most of their weight loss with tirzepatide at more than 3 years, ...